The patient with Herpes Simplex Virus (HSV) encephalitis is
receiving acyclovir (Zovirax). The nurse monitors blood chemistry
test results and urinary output for
a) renal complications related to acyclovir therapy.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.
b) signs and symptoms of cardiac insufficiency.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.
c) signs of relapse.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy. To prevent relapse treatment with acyclovir should continue
for up to 3 weeks.
d) signs of improvement in the patient’s condition.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.
receiving acyclovir (Zovirax). The nurse monitors blood chemistry
test results and urinary output for
a) renal complications related to acyclovir therapy.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.
b) signs and symptoms of cardiac insufficiency.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.
c) signs of relapse.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy. To prevent relapse treatment with acyclovir should continue
for up to 3 weeks.
d) signs of improvement in the patient’s condition.
Monitoring of blood chemistry test results and urinary output will alert
the nurse to the presence of renal complications related to acyclovir
therapy.